According to the Times, GlaxoSmithKline is a lead contender to land the business, although German healthcare group Bayer and air freshener-to-Lemsip group Reckitt Benckiser are also seen as contenders.
Boots has promised to return much of the proceeds from the deal to investors, another factor for keeping shares in positive territory. They were 14p at 629½p in mid-morning trading.